Rhythm Biosciences (ASX:RHY) entered into a strategic distribution service agreement with 4Cyte Pathology, one of Australia's largest independent pathology providers.
The partnership aims to broaden the reach of ColoSTAT, Rhythm's proprietary blood-based test designed for the early detection of colorectal cancer.
Under the terms of the non-exclusive agreement, 4Cyte Pathology will integrate ColoSTAT into its clinical ordering systems across a massive network of over 1,000 patient collection centres spanning New South Wales, Victoria, and Queensland.
The infrastructure allows for seamless patient access: 4Cyte's phlebotomy network will handle sample collection, while the serum samples will be transported to Rhythm’s ISO-accredited laboratory in Parkville for specialised analysis.
The strategic rationale behind the deal focuses on addressing the gaps in current screening methods.
ColoSTAT measures five specific protein biomarkers and serves as a vital alternative for individuals who are unable or unwilling to use traditional faecal-based tests, such as the FIT.
By leveraging 4Cyte's established reporting systems, results will be delivered directly back to referring practitioners.
The agreement requires no upfront payments or minimum volume commitments, allowing Rhythm to invoice patients directly while capitalising on 4Cyte’s vast clinical footprint.